TEP-FDG (n = 67) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Primary population | Secondary and exploratory populations | ||||||||
Overall population (n = 67) | No MI (n = 33) | MI (n = 34) | No omega-3 (n = 29) | Omega-3 (n = 38) | Omega-3 + MI (n = 20) | Omega-3 only (n = 18) | MI only (n = 14) | Placebo (n = 15) | |
Male gender, N (%) | 18 (26.87) | 8 (24.24) | 10 (29.41) | 8 (27.59) | 10 (26.32) | 7 (35.00) | 3 (16.67) | 3 (21.43) | 5 (33.33) |
Age in years, mean (SD) | 76.37 (4.23) | 76.79 (4.24) | 75.97 (4.24) | 75.41 (4.37) | 77.11 (4.02) | 77.10 (4.15) | 77.11 (3.98) | 74.36 (3.95) | 76.40 (4.64) |
BMI (kg/m2), mean (SD) | 26.40 (3.51) | 26.60 (3.97) | 26.21 (3.06) | 26.35 (2.99) | 26.44 (3.91) | 26.34 (3.73) | 26.56 (4.20) | 26.04 (1.84) | 26.65 (3.82) |
Education, N (%) | |||||||||
No diploma or primary school certificate | 18 (27.27) | 9 (27.27) | 9 (27.27) | 6 (21.43) | 12 (31.58) | 7 (35.00) | 5 (27.78) | 2 (15.38) | 4 (26.67) |
Secondary education | 21 (31.82) | 11 (33.33) | 10 (30.30) | 7 (25.00) | 14 (36.84) | 6 (30.00) | 8 (44.44) | 4 (30.77) | 3 (20.00) |
High-school diploma | 9 (13.64) | 4 (12.12) | 5 (15.15) | 6 (21.43) | 3 (7.89) | 2 (10.00) | 1 (5.56) | 3 (23.08) | 3 (20.00) |
University level | 18 (27.27) | 9 (27.27) | 9 (27.27) | 9 (32.14) | 9 (23.68) | 5 (25.00) | 4 (22.22) | 4 (30.77) | 5 (33.33) |
APOE4 carrier, N (%) | 8 (13.79) | 4 (13.33) | 4 (14.29) | 5 (20.00) | 3 (9.09) | 2 (12.50) | 1 (5.88) | 2 (16.67) | 3 (23.08) |
Composite cognitive score, mean (SD) | 0.05 (0.69) | − 0.02 (0.71) | 0.11 (0.68) | 0.08 (0.58) | 0.02 (0.77) | 0.02 (0.80) | 0.03 (0.77) | 0.24 (0.46) | − 0.07 (0.66) |
MMSE total score/30, mean (SD) | 28.19 (1.62) | 28.21 (1.71) | 28.18 (1.55) | 28.45 (1.40) | 28.00 (1.76) | 28.20 (1.54) | 27.78 (1.99) | 28.14 (1.61) | 28.73 (1.16) |
MMSE orientation score/10, mean (SD) | 9.84 (0.41) | 9.82 (0.39) | 9.85 (0.44) | 9.83 (0.38) | 9.84 (0.44) | 9.85 (0.49) | 9.83 (0.38) | 9.86 (0.36) | 9.80 (0.41) |
CDR score, N (%) | |||||||||
CDR = 0 | 27 (40.30) | 14 (42.42) | 13 (38.24) | 12 (41.38) | 15 (39.47) | 8 (40.00) | 7 (38.89) | 5 (35.71) | 7 (46.67) |
CDR = 0.5 | 40 (59.70) | 19 (57.58) | 21 (61.76) | 17 (58.62) | 23 (60.53) | 12 (60.00) | 11 (61.11) | 9 (64.29) | 8 (53.33) |
FCSRT scores, mean (SD) | |||||||||
Free recall/48 | 28.30 (6.81) | 27.67 (7.47) | 28.91 (6.16) | 28.79 (6.22) | 27.92 (7.29) | 27.90 (6.54) | 27.94 (8.25) | 30.36 (5.47) | 27.33 (6.69) |
Total recall/48 | 45.34 (3.45) | 45.03 (3.23) | 45.65 (3.68) | 45.38 (3.00) | 45.32 (3.79) | 45.15 (4.25) | 45.50 (3.33) | 46.36 (2.65) | 44.47 (3.11) |
Delayed free recall/16 | 10.93 (2.66) | 10.82 (3.00) | 11.03 (2.33) | 11.21 (2.06) | 10.71 (3.06) | 10.90 (2.55) | 10.50 (3.60) | 11.21 (2.04) | 11.20 (2.14) |
Delayed total recall/16 | 15.61 (0.85) | 15.48 (1.06) | 15.74 (0.57) | 15.79 (0.49) | 15.47 (1.03) | 15.75 (0.55) | 15.17 (1.34) | 15.71 (0.61) | 15.87 (0.35) |
TMT A, mean (SD) | 44.78 (13.95) | 45.03 (15.38) | 44.53 (12.63) | 43.52 (11.11) | 45.74 (15.85) | 45.30 (13.59) | 46.22 (18.44) | 43.43 (11.53) | 43.60 (11.11) |
TMT B, mean (SD) | 114.36 (36.35) | 116.03 (41.27) | 112.74 (31.48) | 108.56 (35.06) | 118.97 (37.20) | 119.22 (29.85) | 118.69 (45.11) | 103.77 (32.63) | 113.00 (37.84) |
Code test score, mean (SD) | 38.19 (9.20) | 37.97 (8.88) | 38.41 (9.63) | 37.90 (8.89) | 38.42 (9.55) | 37.75 (9.69) | 39.17 (9.61) | 39.36 (9.83) | 36.53 (8.01) |
COWAT score, mean (SD) | 19.66 (6.24) | 19.18 6.59) | 20.12 (5.94) | 20.34 (6.34) | 19.13 (6.20) | 19.65 (6.39) | 18.56 (6.10) | 20.79 (5.38) | 19.93 (7.28) |
CNT score, mean (SD) | 25.70 (8.53) | 24.94 (8.62) | 26.44 (8.51) | 26.52 (7.82) | 25.08 (9.09) | 25.45 (9.00) | 24.67 (9.44) | 27.86 (7.86) | 25.27 (7.83) |
ADCS-ADL PI /45; mean (SD) | 40.00 (4.72) | 39.27 (5.43) | 40.73 (3.83) | 40.45 (4.54) | 39.65 (4.89) | 40.00 (4.16) | 39.28 (5.65) | 41.71 (3.22) | 39.27 (5.34) |
GDS, mean (SD) | 2.33 (1.85) | 2.67 (1.67) | 2.00 (1.98) | 2.41 (2.01) | 2.26 (1.75) | 1.90 (1.74) | 2.67 (1.71) | 2.14 (2.35) | 2.67 (1.68) |
AD-based SUVr, mean (SD) | 1.13 (0.10) | 1.12 (0.08) | 1.14 (0.11) | 1.12 (0.1) | 1.14 (0.09) | 1.14 (0.11) | 1.13 (0.08) | 1.13 (0.11) | 1.11 (0.09) |
DHA (μg/g RBC), mean (SD) | 5.82 (1.41) | 5.66 (1.39) | 5.98 (1.43) | 5.69 (1.24) | 5.92 (1.55) | 5.97 (1.75) | 5.88 (1.36) | 6.00 (0.94) | 5.41 (1.44) |
Medial temporal lobe atrophy, N (%) | |||||||||
Stage 0 | 17 (25.37) | 6 (18.18) | 11 (32.35) | 8 (27.59) | 9 (23.68) | 4 (20) | 5 (27.78) | 7 (50) | 1 (6.67) |
Stage 0.5 | 13 (19.40) | 6 (18.18) | 7 (20.59) | 3 (10.34) | 10 (26.32) | 4 (20) | 6 (33.33) | 3 (21.43) | 0 (0) |
Stage 1 | 25 (37.31) | 14 (42.42) | 11 (32.35) | 13 (44.83) | 12 (31.58) | 8 (40) | 4 (22.22) | 3 (21.43) | 10 (66.67) |
Stage 1.5 | 5 (7.46) | 3 (0.09) | 2 (5.88) | 3 (10.34) | 2 (5.26) | 1 (5) | 1 (5.56) | 1 (7.14) | 2 (13.33) |
Stage 2 | 7 (10.44) | 4 (12.12) | 3 (8.82) | 2 (6.90) | 5 (13.16) | 3 (15) | 2 (11.11) | 0 (0) | 2 (13.33) |